source
- BioNTech spends $205 million on FDA priority review voucher to accelerate oncology pipelineBioNTech has agreed to pay $205 million to acquire an FDA priority review voucher, a tool that can shorten the agency's standard review period from ten months to six months. The voucher was previo…
- Federal panel overseeing preventive care receives blanket ethics waivers despite members' pharma and practice conflictsFederal officials granted blanket ethics waivers to every member of the U.S. Preventive Services Task Force, allowing them to serve despite clear financial conflicts of interest. Documents show so…